Free Trial
LON:SLN

Silence Therapeutics (SLN) Share Price, News & Analysis

Silence Therapeutics logo
GBX 535 -5.00 (-0.93%)
(As of 11/29/2021)

About Silence Therapeutics Stock (LON:SLN)

Key Stats

Today's Range
512
546
50-Day Range
535
535
52-Week Range
411
680
Volume
913,528 shs
Average Volume
80,100 shs
Market Capitalization
£480.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase Ib clinical trials for the treatment of myelodysplastic syndrome; and SLN500 for the treatment of complement-mediated diseases. It has a collaboration agreements with AstraZeneca to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.

Receive SLN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Silence Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SLN Stock News Headlines

Silence Therapeutics: Rising Assets Amid Growing Losses
Download Our Tesla Ebook For Free
Like many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.
Silence Therapeutics files automatic ordinary shares offering
Silence Therapeutics plc (SLNCF)
See More Headlines

SLN Stock Analysis - Frequently Asked Questions

Silence Therapeutics' stock was trading at GBX 535 at the beginning of the year. Since then, SLN shares have increased by 0.0% and is now trading at GBX 535.
View the best growth stocks for 2024 here
.

Silence Therapeutics plc (LON:SLN) released its earnings results on Monday, September, 14th. The company reported ($13.70) EPS for the quarter, beating analysts' consensus estimates of ($21.70) by $8.00.

Shares of SLN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Silence Therapeutics investors own include Arch Therapeutics (ARTH), QuickLogic (QUIK), Asiamet Resources (ARS), ArcBest (ARCB), American Renal Associates (ARA), Apergy (APY) and Anchiano Therapeutics (ANCN).

Company Calendar

Last Earnings
9/14/2020
Today
11/21/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
Pharmaceutical Products
CIK
N/A
Fax
N/A
Employees
100
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£11.35 million
Cash Flow
GBX 84.41 per share
Book Value
GBX 18.20 per share

Miscellaneous

Free Float
N/A
Market Cap
£480.35 million
Optionable
Not Optionable
Beta
N/A
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (LON:SLN) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners